Novel method of diagnosing and treating gliomas

a glioma and glioma technology, applied in the field of cell physiology, neurology and neurooncology, can solve the problems of unsatisfactory, prior art deficient in lack of effective means, etc., and achieve the effects of short exposure time, reduced size of outward current, and reduced current amplitud

Inactive Publication Date: 2005-06-30
SONTHEIMER HARALD W +1
View PDF18 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015] It is still another object of the present invention to demonstrate that glioma cells can be targeted and / or eliminated by a recombinant chlorotoxin fused to a cytotoxic protein.

Problems solved by technology

Due to the common morphological heterogeneity of cells within a single tumor, such classification is not clear-cut and is somewhat unsatisfactory.
Consequently, the prior art is deficient in the lack of effective means of identifying and treating malignant gliomas.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel method of diagnosing and treating gliomas
  • Novel method of diagnosing and treating gliomas
  • Novel method of diagnosing and treating gliomas

Examples

Experimental program
Comparison scheme
Effect test

example 1

Primary Cultures of Human Astrocytomas

[0055] (UAB Brain Tumor Research Laboratories, see Table 1 for details): Freshly resected brain tumor tissue was transported in ice-cold tissue culture medium and necrotic / hemorrhagic portions were removed aseptically. Discrete pieces of tumor tissue were minced finely, triturated, and plated in DMEM / F12 (Dulbecco's modified Eagle's medium mixed equally with Ham's Nutrient Mixture F12 supplemented with 10 mM HEPES, 2 mM L-glutamine) with 20% Fetal Bovine Serum (FBS, Atlanta Biologicals). Cells from minced fragments were replated onto uncoated 12 mm round coverslips for electrophysiology and for GFAP immunocytochemistry. Acutely isolated tumor cells were prepared from fresh biopsy material, as described above with an additional trypsinization step in order to remove cellular debris, and were used for recordings 15-18 hours after plating.

example 2

Cell Lines

[0056] STTG1 cell line (American Type Culture Collection, Rockville, Md.) was grown in DMEM (Gibco) plus 10% FBS (Hyclone). Human Tumor Cell Lines: established cell lines, derived from human malignant gliomas (D54MG, U105MG, U251MG, and U373MG obtained from D. D. Bigner, Duke University) and extraglial human tumors (all from ATCC), were studied in long term (>100) passages (see TABLE I for details). Cells were maintained in DMEM / F12 supplemented with 7% heat-inactivated FBS (Atlanta Biologicals) at 37° C. in a 10% CO2 / 90% air atmosphere. Cells attaining nearly confluent growth were harvested and replated onto uncoated 75 cm2 flasks or uncoated 12 mm circular glass coverslips for electrophysiology and were used 36-72 hours after plating, unless otherwise noted. Viable cell counts were determined by trypan blue exclusion.

TABLE IPrimary cultures and established astrocytoma cell linesCell LineCl−DesignationCell TypePassageGFAPCurrentPrimary culturesUAB4630GBM1unk8 / 8UAB8553...

example 3

Biopsy Tissue

[0057] Freshly resected human brain tumor tissue are collected during surgery in ice-cold tissue culture medium and necrotic / hemorrhagic portions are removed aseptically. Tissue is maintained for 2 / CO2 until used. Ice-cold tissue are embedded in BactoAgar and cut into blocks of 10×10 mm and glued to the bottom of a petri dish mounted to a Vibratome where 200 mm slices are cut. These are transferred to oxygenated saline and maintained at 37° C. until recording.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
voltageaaaaaaaaaa
depolarizing voltageaaaaaaaaaa
morphologyaaaaaaaaaa
Login to view more

Abstract

The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates generally to the fields of cell physiology, neurology and neuro-oncology. More specifically, the present invention relates to a novel method of diagnosing and treating gliomas and meningiomas. [0003] 2. Description of the Related Art [0004] Glial cells comprise a large proportion of the total cell population in the CNS. Unlike neurons, glial cells retain the ability to proliferate postnatally, and some glial cells still proliferate in the adult or aged brain. Uncontrolled glial proliferation can lead to aggressive primary intracranial tumors, the vast majority of which are astrocytomas, and therefore, of glial origin. Tumors of astrocytic origin vary widely in morphology and behavior, and, according to the 1993 WHO classification schema, can be separated into three subsets. Astrocytomas, the lowest grade tumors, are generally well-differentiated and tend to grow slowly. Anaplastic astro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61K47/48C07K14/435C07K16/28C07K16/30G01N33/574
CPCA61K38/00A61K47/48261A61K2039/505C07K14/43522C07K16/28Y10S436/813C07K2319/23C07K2319/55G01N33/57407G01N33/57492G01N2333/705C07K16/3053A61K47/6415
Inventor SONTHEIMER, HARALD W.ULLRICH, NICOLE
Owner SONTHEIMER HARALD W
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap